AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pacific Biosciences of Ca... (PACB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.64

-0.03 (-1.80%)

At close: Jan 28, 2025, 2:02 PM

undefined% (undefined)

Bid	1.63
Market Cap	447.77M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.46
PE Ratio (ttm)	-1.12
Forward PE	n/a
Analyst	Buy

Ask	1.64
Volume	4,420,447
Avg. Volume (20D)	10,640,703
Open	1.66
Previous Close	1.67
Day's Range	1.58 - 1.69
52-Week Range	1.16 - 7.39
Beta	undefined

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 27, 2010

Employees 796

Stock Exchange NASDAQ

Ticker Symbol PACB

Website https://www.pacb.com

Analyst Forecast

According to 13 analyst ratings, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 52.91% from the latest price.

Buy 53.85%

Hold 46.15%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Pacific Biosciences of California Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $40.68M, reflecting a -30.29% YoY shrinking and earnings per share of -0.18, making a -33.33% decrease YoY.

Why Price Moved

4 days ago

-8.84%

Pacific Biosciences of California shares are tradi... Unlock content with Pro Subscription

1 week ago

-7.96%

Pacific Biosciences shares are trading lower after the company issued worse-than-expected preliminary Q4 revenue.

News

5 days ago · zacks.com

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

6 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

1 week ago · zacks.com

PACB Stock Declines Despite Promising HiFi Sequencing Findings

PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.

1 week ago · zacks.com

PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped

PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.

2 weeks ago · zacks.com

PacBio Stock May Gain Following the Collaborated Launch of GutID

PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.

2 weeks ago · zacks.com

PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics

PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.

2 weeks ago · zacks.com

Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today

Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.

2 weeks ago · fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood saw her investments rally in the second half of 2024 after a slow start. The co-founder, CEO, and primary stock picker for Ark Invest is hoping to jump ahead of the market early this year.

1 month ago · zacks.com

Reasons to Retain PacBio Stock in Your Portfolio for Now

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

1 month ago · benzinga.com

Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight

Ark Invest CEO Cathie Wood is doubling down on genomics.

2 months ago · seekingalpha.com

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 millio...

2 months ago · https://thefly.com

PacBio price target lowered to $6 from $7 at Scotiabank

Scotiabank lowered the firm's price target on PacBio to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q3 update,...

2 months ago · zacks.com

PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y

PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.

2 months ago · seekingalpha.com

Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian...

2 months ago · zacks.com

Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall...

2 months ago · zacks.com

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago.

2 months ago · zacks.com

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.